With a suite of products spanning a broad range of therapeutic areas, Forest is delivering on our mission to improve patients' lives.
R&D at Forest is focused on identifying strong, medically relevant product candidates and guiding them through the complex development lifecycle, from proof-of-concept through post-marketing.
DUBLIN, July 1, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has completed the acquisition of Forest Laboratories, Inc. (NYSE: FRX) in a cash and equity transaction currently valued at approximately $28 billion. The combination creates one of the world's fastest-growing specialty pharmaceutical companies, with annual revenues of more than $15 billion anticipated for 2015.
NEW YORK & MORRISVILLE, N.C.--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE:FRX) and Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced that Forest has entered into a definitive agreement to acquire Furiex, a drug development collaboration company, for $95 per share, or approximately $1.1 billion in cash, and up to $30 per share (approximately $360 million in aggregate) in a Contingent Value Right (CVR) that may be payable based on the status of eluxadoline, Furiex’s lead product, as a controlled drug following approval. The acquisition is subject to receipt of customary regulatory approvals and approval by Furiex shareholders.